The Recent Clinical Observation Of Sustained-release 5-fluorouracil Used During Operation In Patients With Advanced Ovarian Elithelial Carcinoma

【Objective】To evaluate the efficacy and side effects of sustained-release 5-Fluorouracil used during operation in the treatment of advanced ovarian elithelial carcinoma.【Methods】Retrospective analysis was utilized to analyze the clinical materials of 62 cases of advanced ovarian cancer in the Nanjing Drum Tower hospital from September 2006 to October 2009,Divided into two groups,30 cases in the group of sustained-release 5-Fluorouracil used during operation combined with TP chemotherapy after operation,and 32 cases in the group of TP chemotherapy after operation.【Result】Preoperative CA₁25 levels of the two groups, the difference was not statistically significan(tP>0.05).After the first cycle chemotherapy,CA₁25 levels in sustained-release 5-Fluorouracil combined with TP chemotherapy group were lower than that in TP chemotherapy group(P<0.05),but there were no significant difference between two groups after second,third or fourth cycle chemotherapy(P> 0.05).For First treatment ovarian cancer patients,CA₁25 levels in sustained-release 5-Fluorouracil combined with chemotherapy group were lower than that in TP chemotherapy group after first cycle(P<0.05),for the patients with recurrent ovarian cancer,CA₁25 levels in sustained-release 5-Fluorouracil combined with TP chemotherapy group were lower than that in TP chemotherapy group after first cycle(P<0.05).After sustained-release 5-Fluorouracil combined with TP chemotherapy treatment, Ascites effective rate was 68%, Pelvic mass was 47% efficiency, Lymph node metastasis rate was 30%,but there were no significant differences between two groups in the toxicities of hypoleukemia, anemia, thrombocytopenia digestive disturbance,liver function damage,renal function damage,phalacrosis (P>0.05)But 6 cases had postoperative abdominal pain stimulation in sustained-release 5-Fluorouracil combined with TP chemotherapy group,but can be tolerated.【Conclusion】Intraoperative use of sustained-release 5-Fluorouracil intraperitoneal chemotherapy was effective and feasible for the advanced ovarian cancer after optimally cytoreductive surgery,In particular to recurrent ovarian cancer,and does not increase toxicity in patients ,so it can be clinically acceptable.